Posted On: 06/24/2014 9:16:44 PM
Post# of 36729
The answer to that question is buried in the well obscured business model of profiting via a consulting fee (see Benz summary of the way Art answered the revenue question on the last conference call). My short answer is... They aren't consulting.
We keep hearing about new Berkeley Bio products, and assuming that they will help the bottom line, but in reality, as I've said, we don't profit from the sales of BBio products. The licensing percentage is a secret. It seems to be a ruse. Benz says the public filings tell the story, well folks, that's the story they tell me.
Where's the revenue for all the products that IGrow and other shareholders bought?
Where's the Monarch Vaporizer revenue? Those aren't pot right?
We keep hearing about new Berkeley Bio products, and assuming that they will help the bottom line, but in reality, as I've said, we don't profit from the sales of BBio products. The licensing percentage is a secret. It seems to be a ruse. Benz says the public filings tell the story, well folks, that's the story they tell me.
Where's the revenue for all the products that IGrow and other shareholders bought?
Where's the Monarch Vaporizer revenue? Those aren't pot right?
(0)
(0)
